Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Cancelled).

2. (Currently Amended) A compound of ~~claim 1 of~~ formula Ib



(Ib),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocydyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_6 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

~~or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a salt of the said compounds~~, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded~~.

3. (Currently Amended) A compound according to claim 1, in which R1 is a heterocyclic radical; lower alkyl substituted by mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_6-C(=O)-, wherein R_6 is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;

R2 is hydrogen;

or a or a salt of the said compounds~~, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded~~.

4. (Currently Amended) A compound according to claim 1, in which R1 is ~~is~~ a lower alkyl substituted by a di-lower alkyl substituted amino, an alkyl substituted 5- or 6- membered heterocyclyl -NH-, heterocyclyl-NH- wherein heterocyclyl is bound to NH via a carbon ring atom; a radical R_4-lower alkyl-O-, wherein R_4 is di-substituted amino; or a radical R_5-C(=O)-, wherein R_5 is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;

R2 is hydrogen;

or a or a salt of the said compounds~~, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded~~.

5. (Currently Amended) A compound according to claim 1, in which R_1 is a lower alkyl substituted by a di-lower alkyl substituted amino, or a C_1-C_4 alkyl-substituted piperazinyl, or a pyrrolidinyl; piperidinyl wherein piperidinyl is bound to NH via a carbon ring atom; a radical R_4- lower alkyl-O-, wherein R_4 is amino di-substituted by lower alkyl; or R_5-C(=O)-, wherein R_5 is a C_1-C_4 alkyl-substituted piperazinyl;

m is 1;

R2 is hydrogen;

or a or a salt of the said compounds~~, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded~~.

6. (Original) A compound chosen from the group consisting of;

{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-pyrrolidin-1-ylmethyl-phenyl)-amine;

{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-dimethyl aminomethyl-phenyl)-amine;

(4-{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;

{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;and

4-{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-benzamide.

7. (Original) A compound of claim 2 wherein R_1 is lower alkyl substituted by amino, lower alkyl substituted by a heterocyclic radical or R_5-C(O)-.

8. (Original) A compound of claim 7 wherein R_1 is lower alkyl substituted by amino.

9. (Original) A compound of claim 7 wherein R_1 is lower alkyl substituted by a heterocyclic radical.

10. (Original) A compound of claim 9 wherein the alkyl portion is methylene and the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

11. (Original) A compound of claim 7 wherein R_1 is R_5-C(O)-.

12. (Original) A compound of claim 11 wherein R_5 is substituted amino or a heterocyclic radical, wherein the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

13. (Previously Presented) A compound of claim 7 wherein R_2 is H.

14. (Previously Presented) A compound of claim 7 wherein m is 1.

15.-17. (Cancelled).

18. (Currently Amended) A method according to claim ~~20,~~ 21, in which the disease is chosen form the group consisting of~~;~~

~~tumours, for example~~ breast tumours, renal tumours, prostate tumours, colorectal tumours, thyroid tumours, ovarian tumours, pancreas tumours, neuronal tumours, lung tumours, uterine tumours, and gastro-intestinal tumours, ~~as well as~~ osteosarcomas, and melanomas.

19. (Cancelled).

20. (Cancelled).

21. (Currently Amended) A method of ~~claim 20,~~ treating a disease which responds to inhibition of IGF-1R in a mammal, which comprises administering to the mammal an effective IGF-1R inhibiting amount of a compound of formula Ib



(Ib),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocydyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is a -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

~~or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;~~

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a pharmaceutically acceptable salt thereof.

22. (Cancelled).

23. (Previously Presented) A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

24.-26. (Cancelled).